Prescriber Scope of Practice for General Psychiatry in Texas

You’ve built a solid psychiatric practice. Your patients trust you. But here’s the question keeping you up at night: Can I legally prescribe that ADHD medication, that benzodiazepine, that buprenorphine script via telehealth — or am I one DEA audit away from serious trouble?

If you’re a psychiatrist or PMHNP navigating telehealth prescribing in 2026, you’re dealing with a regulatory patchwork that would make even a compliance lawyer’s head spin. Federal rules say one thing (for now), your state says another, and the DEA keeps extending temporary policies while promising ‘permanent rules any day now.’

Let’s cut through the noise. This guide breaks down exactly what you can and can’t do when prescribing controlled substances via telehealth — federally and in the states where most psychiatric telehealth happens (California, Texas, Florida, New York, Pennsylvania, Illinois). No legal jargon. Just what matters for your practice.

The Current Reality: Federal Telehealth Flexibilities Extended Through 2026

Here’s where we stand as of early 2026:

You can prescribe Schedule II–V controlled substances via telehealth to new patients without an in-person exam — at least through December 31, 2026. The DEA and HHS announced a fourth extension of COVID-era flexibilities in January 2026, keeping the door open for telepsychiatry while they finalize permanent rules.

What this means practically:

• A new patient books a video appointment for ADHD evaluation
• You conduct a thorough psychiatric assessment via two-way video
• You diagnose ADHD and prescribe Adderall (Schedule II)
• This is currently legal under federal law (assuming you follow standard of care and state rules)

The catch? This is a temporary extension. The Ryan Haight Act — the 2008 federal law requiring an in-person exam before prescribing controlled substances online — is still technically the law of the land. It’s just been suspended under public health emergency authority since March 2020, and that suspension keeps getting extended.

Key requirements under the current extension:

• Use real-time, two-way audio-visual communication for initial evaluations (telephone-only generally doesn’t qualify, except for buprenorphine in specific cases)
• Document your evaluation thoroughly — history, mental status exam, diagnostic reasoning
• Prescribe only for legitimate medical purposes within your scope of practice
• Follow all state laws and PDMP requirements (more on this below)
• If the patient was ever seen in person by any provider, there’s no federal telehealth restriction on prescribing to them going forward

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Rules

The DEA isn’t extending temporary policies forever. In January 2025, they announced three proposed rules that will eventually replace the emergency flexibilities:

1. Special Telemedicine Registration for Schedule II Prescribing

This is the big one for psychiatrists. The DEA proposes creating a Special Telemedicine Prescriber Registration that would allow certain specialists — including board-certified psychiatrists — to prescribe Schedule II controlled substances to new patients via telehealth without any in-person exam.

What this means for you:

• If finalized, you’d apply for this special DEA registration (separate from your regular DEA number)
• Once approved, you could prescribe stimulants, other Schedule II meds for psychiatric conditions via telehealth indefinitely
• Schedule III–V would be available to any qualified prescriber with the registration
• PMHNPs would likely be excluded from Schedule II authority under this registration (it’s currently proposed for physicians in specific specialties)

The rule would also require online telehealth platforms to register with the DEA for the first time and establish a national PDMP to track controlled prescriptions across states.

2. Buprenorphine via Telehealth (6-Month Rule)

For addiction psychiatrists, the DEA proposes allowing up to 6 months of buprenorphine treatment initiated via telehealth (including audio-only) before requiring an in-person visit. After 180 days, you’d need to either see the patient in person or refer them for an in-person evaluation.

This recognizes the reality that medication-assisted treatment for opioid use disorder via telehealth has been a lifeline — and that the old X-waiver system is gone (eliminated in 2023).

3. New Compliance Requirements

Expect more administrative steps:

• Mandatory reporting to regulators on telehealth controlled substance prescribing
• Platform registration and oversight
• Enhanced PDMP integration
• Documentation standards for telehealth encounters

Timeline: These rules are still in public comment phase as of early 2026. Expect finalization sometime in late 2026 or early 2027. Until then, the temporary extension remains in effect.

The Reality Most Providers Miss: State Laws Trump Federal Flexibility

Here’s what catches providers off guard: even if federal law allows telehealth prescribing, your state can impose stricter rules — and many do.

Let’s break down the six states that matter most for psychiatric telehealth:

California: Telehealth-Friendly, But PDMP Compliance is Non-Negotiable

The good news:

• No state-imposed restrictions on telehealth prescribing beyond federal law
• A proper video exam establishes a valid patient relationship
• NPs are transitioning to full practice authority (experienced PMHNPs can practice independently by 2026 in most settings)

The compliance traps:

• Mandatory CURES PDMP check before first prescribing Schedule II–IV controlled substances, then every 4 months for ongoing treatment
• 100% e-prescribing required since January 2022 (paper scripts essentially banned)
• Miss a PDMP check? That’s a Medical Board violation waiting to happen

Bottom line: California welcomes telepsychiatry, but you must stay on top of PDMP queries. Set calendar reminders for your ADHD and anxiety patients.

Texas: Psychiatrists Yes, PMHNPs Have Major Limits

The MD psychiatrist perspective:

• Video exams establish valid patient relationships for prescribing
• No special state restrictions on controlled substances via telehealth (beyond federal rules)
• Must check Texas PDMP before prescribing opioids, benzos, barbiturates, or carisoprodol
• IMLC member (easier multi-state licensing)

The PMHNP reality check:Texas NPs cannot prescribe Schedule II controlled substances in outpatient settings, period. Only in hospitals (for admitted patients) or hospice settings.

What this means:

• A Texas PMHNP cannot prescribe Adderall, Ritalin, Vyvanse via telehealth for outpatient ADHD
• They can prescribe Schedule III–V (Xanax, Ambien, etc.) under physician delegation
• Telehealth platforms in Texas need psychiatrists to handle all Schedule II prescribing

If you’re a PMHNP considering Texas telehealth work, you’ll need an MD partner or the platform needs to employ psychiatrists for stimulant prescriptions.

Florida: The Psychiatric Exception That Saves Telepsychiatry

Florida has one of the strictest telehealth prescribing laws in the country — with a critical carve-out for psychiatry.

The general rule:Schedule II controlled substances cannot be prescribed via telehealth in Florida…

…UNLESS it’s for:

1. Psychiatric disorder treatment ← This is you
2. Inpatient hospital care
3. Hospice care
4. Nursing home residents

What this means:

• You CAN prescribe Adderall for ADHD via telehealth (it’s psychiatric treatment)
• You CAN prescribe Schedule II for other mental health conditions
• You CANNOT prescribe oxycodone for chronic pain via telehealth (not a psychiatric indication)
• Document the psychiatric indication clearly in your notes

Additional Florida requirements:

• Out-of-state providers can register as Florida telehealth providers (no full license needed for telemedicine-only practice)
• Must check E-FORCSE PDMP before prescribing any controlled substance to patients ≥16
• Schedules III–V allowed via telehealth with standard of care
• PMHNPs still need physician collaborative agreements (no independent practice for psych NPs in Florida)

New York: Full Speed Ahead (With Strict PDMP Rules)

The landscape:

• No in-person exam requirement for telehealth prescribing
• Video establishes valid patient relationship
• Experienced PMHNPs (>3,600 hours) practice independently including controlled prescribing
• Strong telehealth parity laws

The compliance requirement that bites:Mandatory I-STOP PDMP check before prescribing ANY Schedule II, III, or IV controlled substance — every single time for new prescriptions.

Plus:

• 100% e-prescribing mandate (all prescriptions, not just controlled) since 2016
• Must register with NY PDMP system

New York was ahead of the curve on telehealth, but they expect rigorous compliance. The I-STOP database check is non-negotiable.

Pennsylvania: Standard of Care Rules, But No Clear Statute

The situation:Pennsylvania doesn’t have comprehensive telehealth legislation yet (multiple bills have stalled). Practice operates under general medical board authority.

What this means:

• Video exams can establish patient relationships for prescribing
• No specific telehealth prescribing bans
• Must check PA PDMP before prescribing opioids or benzos (and for ongoing treatment)
• E-prescribing required for controlled substances since 2019
• PMHNPs need collaborative agreements with (technically two) physicians for prescriptive authority

The gray area:Without explicit telehealth statutes, you’re relying on medical board interpretation of ‘standard of care.’ Documentation is everything. When in doubt, err on the side of more thorough evaluation and documentation.

Illinois: Full NP Practice Available, But Benzo/Schedule II Quirks

For psychiatrists:

• Telehealth prescribing allowed under same standards as in-person
• Mandatory PDMP check before prescribing opioids each time
• E-prescribing required since January 2023
• IMLC member

For PMHNPs:Illinois offers Full Practice Authority for experienced NPs (4,000 hours + extra training), but with a catch:

Even NPs with FPA must enter a consultation relationship with a physician to prescribe benzodiazepines or Schedule II narcotics, and can only prescribe 30-day supplies of those medications at a time.

Practical impact:

• An independent PMHNP in Illinois can manage most psychiatric medications
• For ongoing benzo or Schedule II stimulant treatment, they need a physician consultation relationship (not full supervision, but documented consultation)
• This was a compromise when Illinois passed FPA laws

Psychiatrist vs PMHNP: Scope of Practice Reality Check

This matters more in telehealth than in-person practice because state scope-of-practice laws create hard boundaries on what PMHNPs can do depending on where the patient is located.

Psychiatrists (MD/DO):

Uniform authority across all states:

• Full independent practice everywhere
• Can prescribe all Schedule II–V controlled substances (following DEA + state rules)
• No supervision requirements
• Only limits: state licensure + DEA registration in states where you practice

PMHNPs: State-by-State Variability

What this means for telehealth platforms:

If you’re recruiting PMHNPs, you need to know:

• In Texas, you’ll need MDs available for all Schedule II prescriptions
• In California and New York, experienced NPs can handle the full scope independently
• In Florida and Pennsylvania, you need collaborative agreements in place
• In Illinois, even ‘independent’ NPs need consultation relationships for certain prescribing

This isn’t about one being ‘better’ — it’s about understanding regulatory constraints that affect your practice model and patient access.

The Compliance Checklist: What You Must Do Right Now

Regardless of your state, here’s your baseline compliance framework for telehealth controlled substance prescribing in 2026:

Before the first prescription:

☐ Verify state licensure where the patient is physically located
☐ Confirm DEA registration in that state (or appropriate multi-state registration)
☐ Check the state PDMP (required in most states before first controlled Rx)
☐ Conduct appropriate evaluation via real-time video (document history, mental status exam, diagnostic reasoning)
☐ Obtain informed consent for telehealth services (many states require this)
☐ Document medical necessity for controlled substance prescription

For ongoing treatment:

☐ Periodic PDMP checks (California: every 4 months; others: varies by state and drug class)
☐ E-prescribe all controlled substances (required in most states)
☐ Document follow-up encounters with same rigor as initial visit
☐ Treatment agreements for high-risk medications (some states require for chronic opioid therapy)
☐ Stay current on training (8-hour substance use disorder training required for DEA registration renewals under 2023 MATE Act)

Red flags to avoid:

✗ Prescribing based on questionnaire alone (no real-time interaction)
✗ Telephone-only prescribing for new controlled substance patients (except buprenorphine OUD treatment)
✗ Ignoring state PDMP mandates
✗ Prescribing outside your scope (e.g., PMHNP in Texas writing outpatient Adderall)
✗ Treating patients in states where you lack licensure
✗ Paper prescriptions in states requiring e-prescribing

The Economics of DIY Telehealth Marketing vs Platforms Like Klarity

Here’s where most psychiatrists and PMHNPs hit a wall: understanding these regulations is one thing. Building a compliant, profitable telehealth practice that actually generates qualified patient flow is another.

The myth floating around provider forums: ‘I can acquire telepsychiatry patients for $30–50 through SEO and Google Ads.’

The reality: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200–500+ when you account for:

• Agency or consultant fees for SEO/PPC management ($1,500–3,000/month minimum for quality work)
• Ad spend testing and optimization (mental health keywords on Google Ads run $15–40+ per click)
• Staff time to handle inquiries and qualify leads
• No-show rates from cold leads (often 30–40% for new patient appointments)
• 6–12 months of SEO investment before meaningful organic traffic
• Failed campaigns and wasted spend learning what works

The SEO timeline trap:

Most solo psychiatrists don’t have the expertise or patience for SEO. You’re competing against established practices, directory sites, and content farms. Even with perfect execution, you’re looking at minimum 6 months before you see results, and often closer to a year for competitive markets.

The Google Ads reality:

Yes, you can get clicks for ‘online psychiatrist’ or ‘ADHD medication online.’ But here’s what actually happens:

• $20 per click average for competitive psychiatric keywords
• 3–5% conversion rate from click to booked appointment (if you’re good)
• That’s $400–667 per booked patient in ad spend alone
• Add platform fees, credit card processing, no-shows, and your real cost per seen patient is $500+

Directory listings (Psychology Today, Zocdoc):

• Psychology Today: ~$30/month for basic listing, but you’re one of hundreds on search results pages
• Zocdoc: Charges per booking ($35–100+ depending on specialty and market) PLUS monthly subscription
• Total monthly cost for multiple directory presence: $200–500+
• You’re competing with every other provider in the same city for the same eyeballs

The Platform Alternative: Pay Only for Qualified Patients

This is where platforms like Klarity Health change the economics entirely:

The model:

• Pay a standard listing fee per new patient appointment (similar to Zocdoc’s per-booking model)
• No upfront marketing spend
• No monthly subscription fees
• No wasted ad spend on clicks that don’t convert

What you actually get:

• Pre-qualified patients already matched to your specialty and availability
• Both insurance and cash-pay patient flow
• Built-in HIPAA-compliant telehealth infrastructure (no separate platform costs)
• E-prescribing and EHR integrated
• You control your schedule — only pay when you see patients

The math that matters:

Instead of gambling $3,000–5,000/month on marketing with uncertain ROI, you pay only when a qualified patient books.

Example scenario:

• DIY marketing: $4,000/month spend → 8–10 new patients (if things go well) = $400–500 per patient acquisition
• Platform model: $0 upfront → Pay listing fee per patient seen = Guaranteed ROI, zero risk

For most psychiatrists and PMHNPs — especially those starting out, scaling up, or who simply want to focus on clinical care rather than becoming marketing experts — the platform model removes the entire patient acquisition risk.

When DIY makes sense:

If you have:

• $10,000+ marketing budget to test and optimize for 6–12 months
• Expertise in healthcare SEO and PPC (or budget for top-tier agencies)
• Patience to wait for results while burning through cash
• Time to manage campaigns, test landing pages, qualify leads

Then yes, eventually you might build cost-effective patient acquisition channels.

For everyone else: Platforms that handle patient acquisition and only charge when you see patients are the economically rational choice. You’re trading a fixed cost per patient for all the variable costs, uncertainty, and expertise requirements of DIY marketing.

FAQ: Your Top Questions Answered

Can I prescribe Adderall via telehealth to a new patient in 2026?

Yes, under current federal rules (extended through Dec 2026) you can prescribe Schedule II stimulants via telehealth after a proper video evaluation. However, check your state law:

• California, New York, Illinois: Yes (MD or experienced NP)
• Texas: Yes if you’re an MD; No if you’re an NP in outpatient setting
• Florida: Yes if it’s for psychiatric treatment (document this)
• Pennsylvania: Yes with appropriate evaluation

Always document thoroughly and check PDMP.

Do I need a special DEA registration for telehealth prescribing?

Not currently (through 2026). Your regular DEA registration in the state where the patient is located is sufficient. The proposed ‘Special Telemedicine Registration’ would be a new, additional registration once those rules are finalized (likely 2027).

Can I use telephone-only (no video) for controlled substance prescribing?

Generally no, except:

• Buprenorphine for opioid use disorder (audio-only allowed under current policy)
• Established patients for follow-ups in some states (check state law)

For new patients and Schedule II stimulants/benzos, use real-time video to be compliant and defensible.

What happens if the DEA extensions expire and I have patients on controlled medications?

The DEA has consistently stated that patients already under treatment will not be disrupted. Expect a transition period where:

• Existing patients can continue
• New patients may require in-person evaluation OR
• Providers can obtain the new special telemedicine registration

Monitor DEA announcements closely as we approach end of 2026.

Do PMHNPs need physician supervision for telehealth in all states?

No — it’s state-specific:

• Full practice (no supervision): New York (after 3,600 hrs), California (transitioning)
• Reduced practice (collaboration needed): Pennsylvania, Illinois (unless FPA license)
• Restricted practice (supervision required): Texas, Florida

This applies to both in-person and telehealth practice.

How often do I need to check the PDMP?

Varies by state:

• California: Before first Schedule II–IV prescription, then every 4 months
• New York: Every time you prescribe Schedule II–IV
• Texas: Before prescribing opioids, benzos, barbiturates, carisoprodol
• Florida: Before any controlled substance for patients ≥16
• Pennsylvania: Before opioids/benzos, periodically for ongoing treatment
• Illinois: Each time for opioids

Set systems to comply with your most restrictive state requirement if you practice multi-state.

The Bottom Line: Stay Compliant, Stay Profitable, Stay Sane

Telehealth prescribing of controlled substances in 2026 exists in a regulatory gray zone that’s slowly resolving. Current federal flexibility through end of 2026 gives you room to operate, but state laws impose the real constraints.

Key takeaways:

1. You can prescribe controlled substances via telehealth right now under federal law (video evaluation, appropriate documentation, legitimate medical purpose)

2. State law matters more — know the rules where your patients are located, especially PDMP requirements and scope-of-practice limits for NPs

3. The regulatory landscape is shifting — DEA’s permanent rules will likely arrive in late 2026/early 2027, with special registrations for Schedule II telehealth prescribing

4. Compliance is non-negotiable — PDMP checks, e-prescribing, thorough documentation, and following standard of care protect your license

5. Patient acquisition economics favor platforms over DIY marketing for most providers — guaranteed ROI vs gambling on expensive, expertise-intensive marketing channels

The psychiatrists and PMHNPs building sustainable telehealth practices aren’t trying to DIY everything. They’re focusing on clinical care while leveraging infrastructure that handles patient acquisition, compliance, and technology.

Ready to expand your telepsychiatry practice without the regulatory headaches or marketing gamble?

Join Klarity Health’s provider network and see qualified patients on your schedule, in your states, with built-in compliance and zero upfront marketing spend. You handle the psychiatry. We handle everything else.

Explore Klarity’s Provider Network →

References & Sources

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release, January 2, 2026. Available at: https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Care.’ Press Release, January 16, 2025. Available at: https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47 – Use of Telehealth to Provide Services. 2025 Edition. Available at: http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ March 2023. Available at: https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board. ‘Prescriptive Authority and Supervision FAQs.’ Updated 2024. Available at: https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

6. Substance Abuse and Mental Health Services Administration (SAMHSA). ‘MAT Act Waiver Elimination and New Training Requirements.’ Updated 2023. Available at: https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

7. Tebra (The Intake). ‘State-by-State Breakdown of Nurse Practitioner Practice Authority Laws.’ Updated December 4, 2025. Available at: https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state

8. JD Supra / National Law Review. ‘States and Feds Signal Big Changes to Telehealth Prescribing.’ February 2023. Available at: https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Telehealth regulations continue to evolve. Providers should consult their state medical/nursing boards, legal counsel, and DEA updates for the most current requirements applicable to their specific practice.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices